Literature DB >> 20467344

Poorly enhanced areas of pancreatic adenocarcinomas on late-phase dynamic computed tomography: comparison with pathological findings.

Yuki Hattori1, Toshifumi Gabata, Yoh Zen, Kentaro Mochizuki, Hirohisa Kitagawa, Osamu Matsui.   

Abstract

OBJECTIVES: The aim of the study was to retrospectively compare image findings of poorly enhanced areas (PEAs) of pancreatic adenocarcinomas that show almost no enhancement or obviously hypoattenuating area relative to the surrounding carcinoma on late-phase dynamic computed tomography (CT) with pathological findings.
METHODS: Thirty-nine patients with pancreatic adenocarcinoma underwent dynamic CT and surgery. Poorly enhanced areas were classified according to their size, attenuation value, position, and border on CT imaging and signal intensity on magnetic resonance imaging.
RESULTS: Of the 33 PEAs, 12 showed neoplastic duct-like structure that contained both large tumor gland and dilated pancreatic duct with atypia, 11 showed necrosis, 4 showed retention cyst, 2 showed dilated pancreatic duct without atypia or with limited invasion, 1 showed mucin, and 3 showed no remarkable differences in characteristics compared with surrounding tissue. Neoplastic duct-like structures tended to be well defined (P < 0.01). Necrotic portions tended to show a high attenuation value (P < 0.01) and central position (P < 0.01) and were ill defined (P < 0.01). Retention cysts tended to show a peripheral position (P < 0.01).
CONCLUSIONS: Poorly enhanced areas corresponded to cystic, necrotic, and mucinous components. Image findings demonstrated these characteristics. Necrotic component can be visualized and distinguished with other components and can be a prognostic factor.

Entities:  

Mesh:

Year:  2010        PMID: 20467344     DOI: 10.1097/MPA.0b013e3181dbc583

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer.

Authors:  Yukiko Sugiyama; Yasunari Fujinaga; Masumi Kadoya; Kazuhiko Ueda; Masahiro Kurozumi; Hideaki Hamano; Shigeyuki Kawa
Journal:  Jpn J Radiol       Date:  2012-01-12       Impact factor: 2.374

2.  Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT.

Authors:  Naohiro Furuhashi; Kojiro Suzuki; Yusuke Sakurai; Mitsuru Ikeda; Yuichi Kawai; Shinji Naganawa
Journal:  Eur Radiol       Date:  2014-11-30       Impact factor: 5.315

3.  A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.

Authors:  Ningzi Tian; Dong Wu; Lei Zhu; Mengsu Zeng; Jianke Li; Xiaolin Wang
Journal:  BMC Med Imaging       Date:  2022-07-03       Impact factor: 2.795

4.  Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer.

Authors:  Jian-Feng Gao; Yu Pan; Xian-Chao Lin; Feng-Chun Lu; Ding-Shen Qiu; Jun-Jun Liu; He-Guang Huang
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

5.  Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy.

Authors:  Seung-Seob Kim; Sunyoung Lee; Hee Seung Lee; Seungmin Bang; Mi-Suk Park
Journal:  Abdom Radiol (NY)       Date:  2020-08-03

Review 6.  The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma.

Authors:  Hyungjin Rhee; Mi Suk Park
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

7.  CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery.

Authors:  Liang Zhu; Xiaohua Shi; Huadan Xue; Huanwen Wu; Ge Chen; Hao Sun; Yonglan He; Zhengyu Jin; Zhiyong Liang; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.